Form 4: Onconetix Interim CEO Ralph Schiess Reports Share Conversion
SEC Form 4 Filing
Ralph Schiess, Interim CEO & CSO of Onconetix, Inc., reports the conversion of Series B preferred stock into common stock.
Summary
- On September 24, 2024, Ralph Schiess, Interim CEO & CSO of Onconetix, Inc., reported a transaction involving the conversion of Series B preferred stock into common stock.
- This transaction resulted in the acquisition of 489,160 shares of common stock and the disposal of 495,903 shares.
- Following the reported transaction, Schiess beneficially owns 495,903 shares of common stock.
Sentiment
Score: 5
Explanation: This is a routine regulatory filing related to stock conversion, and doesn't inherently indicate positive or negative sentiment.
Industry Context
Form 4 filings are a routine part of the US financial market and are required by the SEC to provide transparency into the transactions of company insiders.
Stakeholder Impact
- The conversion of preferred stock to common stock may have a slight dilutive effect on existing common shareholders.
Key Dates
| Date | Description |
|---|---|
| 09/24/2024 | Date of transaction: conversion of Series B preferred stock to common stock. |
| 09/26/2024 | Date of signature for the Form 4 filing. |
Keywords
Form 4, Onconetix, Schiess, Preferred Stock, Common Stock, Conversion, Beneficial Ownership, ONCO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.